TriangleFOR PATIENTS · SOURCE READING
Treatment of High-Risk Classic Childhood Hodgkin Lymphoma
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 8, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, visit the Treatment Option Overview section.
Source links and citations
Treatment of newly diagnosed high-risk classic Hodgkin lymphoma in children may include:
Source links and citations
Higher-dose combination chemotherapy.
Source links and citations
Combination chemotherapy with targeted therapy (brentuximab) or immunotherapy (nivolumab).
Source links and citations
Radiation therapy may also be given to the areas with cancer.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice